-
ample opportunities for direct validation in biologically relevant settings. This interdisciplinary atmosphere has been a main catalyst for many past successes: https://europepmc.org/article/MED/35021063
-
prodromal cohorts and link them to clinical readouts and α-synuclein reactivity. Use cutting-edge single-cell and immune-profiling approaches, linked to clinical phenotyping, to discover early biomarkers and
-
murine microenvironments and use high-resolution spatial omics techniques to prioritize molecular factors that may drive the immune cell states. These will then be validated through in vivo screening
-
supervisor(s) you wish to apply for (minimum 1, maximum 3), as listed in the link below. Applications that do not specify a project and supervisor will not be taken into consideration. Step 1: Motivation Field
-
prodromal cohorts and link them to clinical readouts and α-synuclein reactivity. Use cutting-edge single-cell and immune-profiling approaches, linked to clinical phenotyping, to discover early biomarkers and
-
the most likely underlying neuropathological subtypes in FTD and AD patients. The project will make use of genetic information from the largest FTD and AD patient-control cohorts, including
-
The Laboratory of Ion Channel Research (https://voetslab.sites.vib.be/en ), led by Prof. Thomas Voets at the VIB–KU Leuven Center for Brain & Disease Research, is a dynamic hub investigating the